Home / Stocks / Fermenta Biotech Ltd.
FERMENTA

Fermenta Biotech Ltd. Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹462.3

Change

+5.9 (1.29%)

Open

₹455.05

Prev. Close

₹456.4

Day High

₹468.95

Day Low

₹452.0

Volume Analysis

Traded

43,486

Delivered

26,221

Delivery %

60.3%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (1)

  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹487.11 ₹478.03 ₹470.16 ₹461.08 ₹453.21 ₹444.13 ₹436.26
Fibonacci ₹478.03 ₹471.56 ₹467.55 ₹461.08 ₹454.61 ₹450.6 ₹444.13
Camarilla ₹466.96 ₹465.41 ₹463.85 ₹461.08 ₹460.75 ₹459.19 ₹457.64

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

—

1 Week

-2.54%

1 Month

-0.58%

3 Months

-3.36%

6 Months

+53.36%

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹279.15

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

12.21%

Net margin 9.75% × asset turnover 0.75x × equity multiplier 1.67x

Company Overview

Sector

Healthcare

Market Cap

₹1,367 Cr

P/E (TTM)

29.4

ROE

17.3%

Book Value

₹142.0

Face Value

₹5.0

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Fermenta Biotech Ltd. holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 65/100. The strongest factor is Financial Strength (100/100), while Institutional Ownership (41/100) is the weakest area to weigh before deciding. Notably: Promoter holding is falling. FII holding has been rising.

TopFund Score — Fundamentals Quality

65/100 — Good

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

51

Valuation

47

Cash Flow

72

Corporate Governance

68

Momentum

65

Institutional Ownership

41

Business Quality

72

Risk & Volatility

68

Liquidity

44

From Screener.in

  • −Promoter holding has decreased over last quarter: -3.96%
  • −The company has delivered a poor sales growth of 6.85% over past five years.
  • −Company has a low return on equity of 12.9% over last 3 years.
  • −Working capital days have increased from 48.7 days to 96.2 days

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Newspaper publication regarding unaudited financial results (standalone and consolidated) for the quarter and half year ended September 30, 2026.

Fermenta reports H1FY27 revenue of INR 261.9 crore, EBITDA down 34% and PAT down 52% YoY.

Board approved closure of UK subsidiary Fermenta Biotech (UK) Limited on November 5, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 57 99 97 78 95 156 140 136 130 137 122 122 133
Expenses + 71 74 92 77 76 103 103 108 104 112 102 104 113
Operating Profit -14 25 5 1 19 53 37 28 27 25 20 18 20
OPM % -24.44% 25.39% 5.53% 1.02% 19.76% 34.04% 26.42% 20.73% 20.46% 18.17% 16.45% 14.83% 15.16%
Other Income + -6 3 5 3 3 2 4 9 5 1 14 4 3
Interest 4 5 3 3 4 4 3 3 3 3 3 3 4
Depreciation 6 6 6 6 6 6 6 6 5 5 5 5 5
Profit before tax -29 16 1 -6 12 45 32 28 24 17 26 15 14
Tax % 0.0% 37.81% 884.62% 0.0% 5.92% 16.43% -4.19% 23.07% 25.17% 31.24% 29.03% 35.13% 33.75%
Net Profit + -29 10 -7 -6 11 38 33 22 18 12 19 10 9
EPS in Rs -10 3 -2 -2 4 13 12 7 6 4 7 3 3
Raw PDF — — — — — — — — — — — — —
YoY Sales growth -42 80 -7 -5 67 58 44 74 37 -12 -13 -11 2

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 142 155 164 302 403 292 376 397 349 335 468 523 513
Expenses + 126 134 152 209 248 225 293 335 330 307 352 422 430
Operating Profit 16 21 12 93 156 66 83 62 18 28 115 101 83
OPM % 11.0% 13.0% 7.0% 31.0% 39.0% 23.0% 22.0% 16.0% 5.0% 8.0% 25.0% 19.0% 16.0%
Other Income + 0 1 3 9 6 12 8 8 -20 4 7 29 23
Interest 4 6 10 14 21 20 19 18 21 17 15 13 12
Depreciation 9 8 10 12 12 15 20 26 28 25 24 22 21
Profit before tax 3 7 -6 76 129 43 52 27 -51 -10 83 96 73
Tax % 67.0% 61.0% 49.0% 28.0% 8.0% -37.0% 18.0% 44.0% 4.0% 143.0% 8.0% 27.0% —
Net Profit + 1 2 -9 46 117 60 43 15 -53 -24 76 70 50
EPS in Rs 0 0 -4 12 43 20 15 5 -17 -8 26 24 17
Dividend Payout % 249.0% -51.0% -5.0% 2.0% 1.0% 24.0% 16.0% 23.0% -7.0% -16.0% 9.0% 15.0% —
Sales growth 2 9 6 84 34 -28 29 6 -12 -4 39 12 -9

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 129 128 142 122 246 295 346 358 301 274 348 392 404
Borrowings + 71 89 87 173 209 224 232 239 220 139 115 113 109
Other Liabilities + 60 70 75 87 92 80 94 96 102 120 137 128 169
Total Liabilities 262 288 307 385 551 614 687 707 637 548 614 648 696
Fixed Assets + 85 168 172 177 178 200 263 299 267 269 227 220 217
CWIP 65 6 5 4 22 71 57 35 45 2 16 13 23
Investments 18 15 18 10 8 0 0 0 3 0 0 0 0
Other Assets + 94 99 112 193 344 342 367 373 321 277 372 414 456
Total Assets 262 288 307 385 551 614 687 707 637 548 614 648 696
Equity Capital 2 2 2 2 5 14 14 14 14 14 15 14 14

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 15 4 2 59 90 34 63 43 116 105 41 93
Cash from Investing Activity + -18 -13 7 -101 -97 -44 -41 -26 -55 -16 0 -43
Cash from Financing Activity + 1 10 -12 89 12 -47 -1 -22 -41 -91 -51 -42
Net Cash Flow -2 1 -4 47 6 -57 21 -4 19 -1 -10 8
Free Cash Flow -20 -25 -17 42 55 -34 7 6 76 86 38 63
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 119 35 35 83 79 73 92 85 610 370 38 108

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 62.06% → 60.12%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Others 1.89% 1.89% 1.82% 1.47% 0.94% 0.89% 0.89% 1.14% 1.9% 2.58% 2.55% 2.39%
Public 36.05% 36.05% 36.11% 36.41% 36.98% 35.0% 35.0% 34.75% 33.99% 33.32% 33.19% 36.43%
Promoters 62.06% 62.06% 62.06% 62.06% 62.06% 64.08% 64.08% 64.08% 64.08% 64.08% 64.08% 60.12%
FII 0.0% 0.0% 0.0% 0.05% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.13% 1.05%
DII 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.04% 0.0%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Fermenta Biotech Ltd. (this stock) 1,367 29.4 3.27 17.3%
Anlon Healthcare Limited 1,348 37.8 5.25 18.4%
Shalby Limited 1,340 34.2 1.31 2.45%
Jagsonpal Pharmaceuticals 1,402 — 5.82 —
Kopran Ltd 1,281 32.6 2.44 4.91%
Amrutajan Health Ltd 1,461 71.7 13.58 20.0%
Gujarat Kidney N Sup Sp L 1,269 66.8 4.82 11.1%

Which Mutual Funds Hold Fermenta Biotech Ltd.?

Frequently Asked Questions about Fermenta Biotech Ltd.

Community Sentiment

What are other investors saying about Fermenta Biotech Ltd.?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.